Skip to main content


Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Quick Connect

Vonoprazan Fumarate

Vonoprazan Fumarate API

Vonoprazan Fumarate-API

CAS Number: 881681-01-2

Therapeutic Category
Gastro-Intestinal - GI
API Technology
Small molecule
Dose Form
Oral Solid/Tablets
Dr Reddy's Development Status
Available
Available Regulatory Filing
USDMF
Brazil DMF
Innovator Brand (USA)
Takecab
No Document Available
Off

Mechanism of Action

Vonoprazan fumarate is a proton pump inhibitor that works by reducing the amount of acid produced in the stomach. It does this by blocking the activity of the enzyme H+/K+ ATPase, which is responsible for producing gastric acid.

The mechanism of action of vonoprazan fumarate involves the inhibition of the final step of acid secretion, which is the transport of hydrogen ions into the gastric lumen. This leads to a decrease in the production of gastric acid and therefore reduces the amount of acid that is available to cause damage to the esophagus, stomach, or duodenum.

Vonoprazan fumarate has a rapid onset of action and provides sustained acid suppression for 24 hours with a single daily dose, making it an effective treatment for a variety of acid-related conditions such as gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD), and Zollinger-Ellison syndrome.

Indication

Vonoprazan fumarate is indicated for the treatment of various acid-related conditions, including:

Gastroesophageal Reflux Disease (GERD): Vonoprazan fumarate is used to relieve symptoms of GERD, such as heartburn, regurgitation, and chest pain.

Peptic Ulcer Disease (PUD): Vonoprazan fumarate is used to treat PUD, which is caused by the formation of sores or ulcers in the stomach or duodenum.

Zollinger-Ellison Syndrome: Vonoprazan fumarate is used to treat Zollinger-Ellison syndrome, a rare condition in which the stomach produces too much acid.

It is important to note that vonoprazan fumarate should be used only under the supervision of a healthcare provider, and the dose and duration of treatment should be based on the individual's medical condition and response to therapy.

Dr. Reddy's Expertise

Headquartered in Hyderabad, India, Dr. Reddy's Laboratories is one of the leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Vonoprazan Fumarate API. Dr. Reddy's API business is a preferred partner to pharma companies across the US, Europe, Brazil, Latin America, Japan, China, Korea, Middle East and other emerging markets.

Dr. Reddy's API business thrives on the deep technical strengths established over the last 30+ years in the development and manufacture of complex APIs such as steroids, peptides, complex long chain molecules and highly potent APIs (HPAPIs / oncology drugs). This expertise is complemented by our prowess in intellectual property and regulatory affairs which helps us consistently meet and exceed regulatory standards. Dr. Reddy's Vonoprazan Fumarate API is the outcome of the extensive expertise in R&D, IP, and Regulatory.

A key component in helping our customers be first to market is a responsive supply chain. We achieve this by making sure that all our facilities are operating efficiently and to the latest standards of quality, safety, and productivity. A strong interconnect between business and factories allows for a quick reaction to dynamic market changes, so that we can avert shortages and meet sudden surges in demand.

Gastrointestinal API Products:

Learn More

Contact Us

Please fill in the following form for API Requirement & we'll get back to you shortly

We are here to help, if you have any country specific requirements.

Disclaimer

No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.